Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development
01 févr. 2022 16h05 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious...
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia
06 déc. 2021 07h00 HE
|
Kronos Bio, Inc.
Data in the second half of 2023 could potentially lead to accelerated approvalIf approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit...
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742
29 nov. 2021 07h00 HE
|
Kronos Bio, Inc.
Initial data demonstrate long plasma half-life and dose-dependent target inhibition Trial is continuing to enroll patients on three-day on, four-day off schedule SAN MATEO, Calif. and CAMBRIDGE,...
Kronos Bio Announces Participation in Upcoming Investor Conferences
24 nov. 2021 07h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Appoints Roshawn Blunt to Board of Directors
11 nov. 2021 16h05 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results
09 nov. 2021 16h10 HE
|
Kronos Bio, Inc.
Company today announces progression of two discovery programs within its pipeline Highlights from the quarter include presentation of preclinical data on the company’s CDK9 inhibitor KB-0742 at...
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform
08 nov. 2021 16h44 HE
|
Kronos Bio, Inc.
Kronos to receive broad access to Tempus’ real-world data and proprietary tools and materials to expand preclinical hypotheses testing capabilities and inform more streamlined clinical trial design ...
Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology
04 nov. 2021 07h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021
30 sept. 2021 16h36 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...
Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations
14 sept. 2021 08h00 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...